ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
ALXO Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
ALX Oncology Holdings Inc.NASDAQ: ALXO
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities rises 20.8% from a year ago
Other non-current liabilities stood at $6.8M at the end of Q1 FY2026, up 20.8% from a year earlier and down 20.1% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.
Context
- Other non-current liabilities amounted to 3.8% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +20.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.51M USD
- Year-over-year change
- +729.6%
- 4-year CAGR
- +46.7%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.51M | +729.6% |
| FY2024 | 2024-12-31 | 1.03M | -15.8% |
| FY2023 | 2023-12-31 | 1.22M | -77.1% |
| FY2022 | 2022-12-31 | 5.31M | +188.8% |
| FY2021 | 2021-12-31 | 1.84M | — |
Other Non-current Liabilities vs competitors
How ALXO compares with its peers on the latest reported figures
- ALXO's Mar 2026 other non-current liabilities of $6.8M is the 2nd highest of the 8 companies compared; the peer median is $87K.
- Its year-over-year change of +20.8% is the 4th highest of 6, against a peer median of +45.6%.
- Other non-current liabilities amounts to 3.8% of total assets for ALXO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $108.9M | +2649.2% | +50.9% | 14.8% | |
| Mar 2026 | $6.8M | +20.8% | +17.0% | 3.8% | |
| Mar 2026 | $973K | +201.2% | -54.4% | 0.1% | |
| Mar 2026 | $418K | +45.6% | +21.6% | 0.3% | |
| Mar 2026 | $87K | +0.0% | — | 0.0% | |
| Mar 2026 | $1K | -99.9% | -27.3% | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ALXO) | $87K | +45.6% | -2.8% | 0.0% | |
Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 363.67M | 48.82M | 22.41M | 17.57M | 16.37M |
| Short-term Investments | 0 | 217.39M | 160.33M | 110.19M | 28.42M |
| Net Receivables | 0 | 0 | 0 | 892K | 298K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.76M | 5.92M | 5.7M | 5.64M |
| Total Current Assets | 367.02M | 270.97M | 188.66M | 134.35M | 50.73M |
| Property, Plant & Equipment (Net) | 3.47M | 9.81M | 10.84M | 9.63M | 1.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 16.7M | 35.41M | 3.52M | 3.49M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 9.69M | 9.01M | 7.64M | 267K | 3.63M |
| Total Non-current Assets | 13.16M | 35.52M | 53.89M | 13.42M | 8.32M |
| Total Assets | 380.18M | 306.49M | 242.55M | 147.78M | 59.05M |
| Account Payables | 3.76M | 8.07M | 8.59M | 4.5M | 4.91M |
| Short-term Debt | 0 | 0 | 0 | 435K | 5.22M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.53M | 4.72M | 6.7M | 5.97M | 14.42M |
| Total Current Liabilities | 15.3M | 28.33M | 36M | 18.5M | 24.55M |
| Long-term Debt | 0 | 9.39M | 9.64M | 9.47M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.84M | 5.31M | 1.22M | 1.03M | 8.51M |
| Total Non-current Liabilities | 1.84M | 14.7M | 16.84M | 15.66M | 8.51M |
| Total Liabilities | 17.13M | 43.03M | 52.84M | 34.16M | 33.07M |
| Common Stock | 41K | 41K | 50K | 53K | 54K |
| Retained Earnings | (201.99M) | (325.47M) | (486.27M) | (621.12M) | (722.82M) |
| Accumulated OCI | (0) | (845K) | 256K | 275K | 28K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 363.05M | 263.46M | 189.71M | 113.62M | 25.98M |
| Total Debt | 742K | 10.43M | 17.2M | 16.98M | 5.22M |
| Net Debt | (362.93M) | (38.39M) | (5.21M) | (589K) | (11.16M) |
ALX Oncology Holdings Inc.
NASDAQ:ALXO
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.